Due: May 20, 2026
CPE CBRND is conducting essential market research for a new initiative dedicated to identifying and advancing mature, portable, and integrated mNGS systems for clinical diagnostics. The program is focused on overcoming technical and regulatory hurdles currently preventing deployment of mNGS as a routine clinical diagnostic tool, particularly in resource-limited or austere settings.
Unlike targeted assays, mNGS offers comprehensive and unbiased detection of pathogens (i.e., viral, bacterial, fungal, and parasitic) from a human clinical sample (e.g. blood, respiratory sample, or other minimally invasive sample types). This capability is essential for diagnosing infections of unknown origin, traditional, novel or genetically modified threats, providing molecular data for outbreak investigations, and enabling informed decisions by Department of War (DoW) leadership.We are seeking collaboration with innovative industry partners who are developing cutting-edge, end-to-end solutions
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium (MCDC). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.